Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders

CNS Spectrums

Volumn 10, Issue 3, 2005, Pages 176-179

  Crane, Daniel L ^a,b  

^a New York University ^*  (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; GABAPENTIN; HALOPERIDOL; IBUPROFEN; LEVOTHYROXINE; LITHIUM; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; ZIPRASIDONE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT FAILURE; UNITED STATES; URINE RETENTION; VISUAL IMPAIRMENT;

EID: 16844364727     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900010002     Document Type: Article

References (49)

1. Lepine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry. 2002;63(suppl 14)4-8.
2. Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry. 1996;57(suppl 10):11-18.
3. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157:669-682.
4. Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety. 1999;9:107-116.
5. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36-44.
6. Roy-Byrne P, Cowley DS. Clinical approach to treatment-resistant panic disorder. In: Rosenbaum JF, Pollack MH, eds. Panic Disorder and its Treatment. New York, NY: Marcel Dekker; 1998:205-227.
7. Coplan JD, Tiffon L, Gorman JM. Therapeutic strategies for the patient with treatment-resistant anxiety. J Clin Psychiatry. 1993;54(suppl):69-74.
8. Hollander E, Beinstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry. 2002;63(suppl 6):20-29.
9. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry. 1999;156:1834-1835.
10. Etxebeste M, Aragues E, Malo P, Pacheco L. Olanzapine and panic attacks. Am J Psychiatry. 2000;157:659-660.
11. Marusic A, Farmer A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry. 2000;177:567.
12. Sun TF, Lin PY, Wu CK. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J. 2001;24:587-592.
13. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2002;17:37-40.
14. Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996;57:303-336.
15. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999;60:524-527.
16. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000;61:514-517.
17. Pfanner C, Marazziti D, Dell'Osso L, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000;15:297-301.
18. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open-study. Can J Psychiatry. 2001;46:356-358.
19. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002;63:700-703.
20. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:619-623.
21. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115-119.
22. McDougle CJ, Eppetson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.
23. Hollander E, Rossi NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6:397-401.
24. Takahashi H, Higuchi H, Shimizu T. Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone. J Neuropsychiatry Clin Neurosci. 2001;13:113-114.
25. Khaldi S, Komreich C, Dan B, Pelc L. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol 2003;23:100-101.
26. Matthew SJ, Coplan JD, German JM. Management of treatment-refractory panic disorder. Psychopharmacol Bull. 2001;35:97-110.
27. Takahashi H, Sugita T, Yoshida K, Higuchi H, Shimizu T. Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports. J Neuropsychiatry Clin Neurosci. 2004;16:113-115.
28. Mottard JP, de la Sablonniere JF. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry. 1999;156:799-800.
29. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001;26:55-59.
30. Alevizos B, Lykouras L, Zervas IM, Christodoulou GN. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001;26:55-59.
31. Alevizos B, Lykouras L, Zervas IM, Christodoulou GN. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol. 2002;22:461-467.
32. Diler RS, Yolga A, Avci A, Scahill L. Risperidone-induced obsessive-compulsive symptoms in two children. J Child Adolesc Psychopharmacol. 2003;13(suppl 1):S89-S92.
33. Levy E, Margolese HC, Sultan S. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine. Can J Psychiatry. 2003;48:709-710.
34. Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry. 1998;155:855.
35. Lykouras L, Zervas IM, Gournellis R, Malliori M, Rabavilas A. Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol. 2000;10:385-387.
36. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
37. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368:277-283.
38. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
39. Ability [package insert]. Rockville, Md: Otsuka America Pharmaceutical, Inc; 2004.
40. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48:229-237.
41. Arato M, O'Connor R, Meltzer HY; ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 ing/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207-215.
42. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol 2002;22:206-210.
43. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23-45.
44. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand. 2000;101:416-432.
45. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q. 2002;73:297-311.
46. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
47. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
48. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6-12.
49. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825.